| Literature DB >> 29048889 |
Marco Fragai1,2, Giuseppina Comito3, Lorenzo Di Cesare Mannelli4, Roberta Gualdani1, Vito Calderone1,2, Alexandra Louka2, Barbara Richichi1, Oscar Francesconi1, Andrea Angeli4, Alessio Nocentini4, Paola Gratteri4, Paola Chiarugi3, Carla Ghelardini, Francesco Tadini-Buoninsegni1, Claudiu T Supuran4, Cristina Nativi1,5.
Abstract
Oxaliplatin (OXA) is a valuable and largely used cancer drug which induces a serious and intractable neuropathy. The lipoyl-homotaurine derivative (ADM_12) reverts in vivo OXA-induced neuropathy, and it is an effective antagonist of the nociceptive sensor channel TRPA1. Unprecedentedly, this safe analgesic showed a synergy with OXA in vitro and proved to inhibit CA IX, a relevant therapeutic target, clearly interfering with pancreatic cancer cells' aggressiveness.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29048889 DOI： 10.1021/acs.jmedchem.7b01237
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446